References
1. Johnson A, Severson E, Gay L, et al. Comprehensive Genomic Profiling of 282 Pediatric Low- and High-Grade Gliomas Reveals Genomic Drivers, Tumor Mutational Burden, and Hypermutation Signatures. Oncologist 2017;22(12):1478-1490. (In eng). DOI: 10.1634/theoncologist.2017-0242.
2. Kumar R, Liu APY, Orr BA, Northcott PA, Robinson GW. Advances in the classification of pediatric brain tumors through DNA methylation profiling: From research tool to frontline diagnostic. Cancer 2018;124(21):4168-4180. (In eng). DOI: 10.1002/cncr.31583.
3. Yarchoan M, Hopkins A, Jaffee EM. Tumor Mutational Burden and Response Rate to PD-1 Inhibition. N Engl J Med 2017;377(25):2500-2501. (In eng). DOI: 10.1056/NEJMc1713444.
4. Roy DM, Walsh LA, Chan TA. Driver mutations of cancer epigenomes. Protein & Cell 2014;5(4):265-296. DOI: 10.1007/s13238-014-0031-6.
5. Shao C, Li G, Huang L, et al. Prevalence of High Tumor Mutational Burden and Association With Survival in Patients With Less Common Solid Tumors. JAMA Network Open 2020;3(10):e2025109-e2025109. DOI: 10.1001/jamanetworkopen.2020.25109.
6. Wang L, Ge J, Lan Y, et al. Tumor mutational burden is associated with poor outcomes in diffuse glioma. BMC Cancer 2020;20(1):213. (In eng). DOI: 10.1186/s12885-020-6658-1.
7. Goodman AM, Kato S, Bazhenova L, et al. Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers. Mol Cancer Ther 2017;16(11):2598-2608. (In eng). DOI: 10.1158/1535-7163.Mct-17-0386.
8. Stenzinger A, Allen JD, Maas J, et al. Tumor mutational burden standardization initiatives: Recommendations for consistent tumor mutational burden assessment in clinical samples to guide immunotherapy treatment decisions. Genes Chromosomes Cancer 2019;58(8):578-588. (In eng). DOI: 10.1002/gcc.22733.
9. Patel RR, Ramkissoon SH, Ross J, Weintraub L. Tumor mutational burden and driver mutations: Characterizing the genomic landscape of pediatric brain tumors. Pediatr Blood Cancer 2020;67(7):e28338. (In eng). DOI: 10.1002/pbc.28338.
10. Cancer gene census. May 2021 ed: Catalogue of Somatic Mutations in Cancer; 2021.
11. Khagi Y, Goodman AM, Daniels GA, et al. Hypermutated Circulating Tumor DNA: Correlation with Response to Checkpoint Inhibitor-Based Immunotherapy. Clin Cancer Res 2017;23(19):5729-5736. (In eng). DOI: 10.1158/1078-0432.Ccr-17-1439.
12. Kaufmann WK, Paules RS. DNA damage and cell cycle checkpoints. Faseb j 1996;10(2):238-47. (In eng). DOI: 10.1096/fasebj.10.2.8641557.
13. Dai Y, Sun C, Feng Y, Jia Q, Zhu B. Potent immunogenicity in BRCA1-mutated patients with high-grade serous ovarian carcinoma. J Cell Mol Med 2018;22(8):3979-3986. (In eng). DOI: 10.1111/jcmm.13678.
14. Birkbak NJ, Kochupurakkal B, Izarzugaza JMG, et al. Tumor Mutation Burden Forecasts Outcome in Ovarian Cancer with BRCA1 or BRCA2 Mutations. PLOS ONE 2013;8(11):e80023. DOI: 10.1371/journal.pone.0080023.
15. Willis C, Fiander M, Tran D, et al. Tumor mutational burden in lung cancer: a systematic literature review. Oncotarget 2019;10(61):6604-6622. (In eng). DOI: 10.18632/oncotarget.27287.
16. Rivlin N, Brosh R, Oren M, Rotter V. Mutations in the p53 Tumor Suppressor Gene: Important Milestones at the Various Steps of Tumorigenesis. Genes Cancer 2011;2(4):466-74. (In eng). DOI: 10.1177/1947601911408889.
17. Wu S, Wang L, Li W, et al. Comparison between the first-line and second-line immunotherapy drugs in the progression-free survival and overall survival in advanced non-small cell lung cancer: a systematic review and meta-analysis of randomized controlled trials. Ann Palliat Med 2021;10(2):1717-1726. (In eng). DOI: 10.21037/apm-20-449.
18. Rizvi NA, Hellmann MD, Snyder A, et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 2015;348(6230):124-8. (In eng). DOI: 10.1126/science.aaa1348.
19. Snyder A, Makarov V, Merghoub T, et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med 2014;371(23):2189-2199. (In eng). DOI: 10.1056/NEJMoa1406498.
20. Zheng M. Tumor mutation burden for predicting immune checkpoint blockade response: the more, the better. Journal for ImmunoTherapy of Cancer 2022;10(1):e003087. DOI: 10.1136/jitc-2021-003087.
21. Sha D, Jin Z, Budczies J, Kluck K, Stenzinger A, Sinicrope FA. Tumor Mutational Burden as a Predictive Biomarker in Solid Tumors. Cancer Discovery 2020;10(12):1808-1825. DOI: 10.1158/2159-8290.Cd-20-0522.
22. Hellmann MD, Ciuleanu TE, Pluzanski A, et al. Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden. N Engl J Med 2018;378(22):2093-2104. (In eng). DOI: 10.1056/NEJMoa1801946.
23. Valero C, Lee M, Hoen D, et al. The association between tumor mutational burden and prognosis is dependent on treatment context. Nature Genetics 2021;53(1):11-15. DOI: 10.1038/s41588-020-00752-4.
24. Ota N, Yoshimoto Y, Darwis NDM, et al. High tumor mutational burden predicts worse prognosis for cervical cancer treated with radiotherapy. Japanese Journal of Radiology 2022;40(5):534-541. DOI: 10.1007/s11604-021-01230-5.
25. Long AH, Morgenstern DA, Leruste A, Bourdeaut F, Davis KL. Checkpoint Immunotherapy in Pediatrics: Here, Gone, and Back Again. American Society of Clinical Oncology Educational Book 2022(42):1-14. DOI: 10.1200/edbk_349799.
26. Melcher V, Kerl K. The Growing Relevance of Immunoregulation in Pediatric Brain Tumors. Cancers (Basel) 2021;13(22) (In eng). DOI: 10.3390/cancers13225601.
27. A Study of Bempegaldesleukin (BEMPEG: NKTR-214) in Combination With Nivolumab in Children, Adolescents and Young Adults With Recurrent or Treatment-resistant Cancer. ClinicalTrials.gov.
28. INFORM2 Study Uses Nivolumab and Entinostat in Children and Adolescents With High-risk Refractory Malignancies. Clinical Trial.
29. Testing the Combination of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) in Children, Adolescent, and Young Adult Patients With Relapsed/Refractory Cancers That Have an Increased Number of Genetic Changes, The 3CI Study. Clinical Trial.
30. H3.3K27M Peptide Vaccine With Nivolumab for Children With Newly Diagnosed DIPG and Other Gliomas. Clinical Trial.
31. A Study to Evaluate the Safety and Efficacy of Nivolumab Monotherapy and Nivolumab in Combination With Ipilimumab in Pediatric Participants With High Grade Primary Central Nervous System (CNS) Malignancies. Clinical Trial.
32. Marcus L, Fashoyin-Aje LA, Donoghue M, et al. FDA Approval Summary: Pembrolizumab for the Treatment of Tumor Mutational Burden-High Solid Tumors. Clin Cancer Res 2021;27(17):4685-4689. (In eng). DOI: 10.1158/1078-0432.Ccr-21-0327.
33. Mackay A, Burford A, Molinari V, et al. Molecular, Pathological, Radiological, and Immune Profiling of Non-brainstem Pediatric High-Grade Glioma from the HERBY Phase II Randomized Trial. Cancer Cell 2018;33(5):829-842.e5. (In eng). DOI: 10.1016/j.ccell.2018.04.004.
34. McGrail DJ, Pilié PG, Rashid NU, et al. High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types. Ann Oncol 2021;32(5):661-672. (In eng). DOI: 10.1016/j.annonc.2021.02.006.
35. Capper D, Engel NW, Stichel D, et al. DNA methylation-based reclassification of olfactory neuroblastoma. Acta Neuropathol 2018;136(2):255-271. (In eng). DOI: 10.1007/s00401-018-1854-7.
36. Ferreyra Vega S, Olsson Bontell T, Corell A, Smits A, Jakola AS, Carén H. DNA methylation profiling for molecular classification of adult diffuse lower-grade gliomas. Clinical Epigenetics 2021;13(1):102. DOI: 10.1186/s13148-021-01085-7.